Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery and development of innovative therapies to combat life-threatening infectious diseases. The company’s primary focus is on addressing the urgent medical challenge posed by antimicrobial resistance (AMR) through differentiated drug candidates, including both therapeutic monoclonal antibodies and novel anti-infectives. Aridis leverages proprietary technology platforms, such as ⅄PEX and MabIgX®, to rapidly identify and develop human-derived monoclonal antibodies that are targeted at neutralizing diverse pathogens. With an advanced pipeline, Aridis is working on several late-stage programs, notably AR-301, a fully human immunoglobulin 1 antibody targeting Staphylococcus aureus alpha-toxin for the treatment of hospital-acquired and ventilator-associated pneumonia, as well as therapies for chronic lung infections and other resistant bacteria. The company’s research addresses an unmet need in infectious disease treatment, aiming to expand the standards of care and improve outcomes for patients with serious respiratory and hospital-acquired infections. Founded in 2003 and headquartered in Los Gatos, California, Aridis Pharmaceuticals plays a critical role in the global effort to mitigate the threat of drug-resistant pathogens and viral pandemics.